PMID- 32445451
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210616
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 26
IP  - 39
DP  - 2020
TI  - AMPK and its Activator Berberine in the Treatment of Neurodegenerative Diseases.
PG  - 5054-5066
LID - 10.2174/1381612826666200523172334 [doi]
AB  - Neurodegenerative disorders are heterogeneous diseases associated with either 
      acute or progressive neurodegeneration, causing the loss of neurons and axons in 
      the central nervous system (CNS), showing high morbidity and mortality, and there 
      are only a few effective therapies. Here, we summarized that the energy sensor 
      adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK), and its agonist 
      berberine can combat the common underlying pathological events of 
      neurodegeneration, including oxidative stress, neuroinflammation, mitochondrial 
      disorder, glutamate excitotoxicity, apoptosis, autophagy disorder, and disruption 
      of neurovascular units. The abovementioned effects of berberine may primarily 
      depend on activating AMPK and its downstream targets, such as the mammalian 
      target of rapamycin (mTOR), sirtuin1 (SIRT1), nuclear factor erythroid-2 related 
      factor-2 (Nrf2), nuclear factor-kappaB (NF-kappaB), phosphoinositide 3-kinase/protein 
      kinase B (PI3K/Akt), nicotinamide adenine dinucleotide (NAD+), and p38 
      mitogen-activated protein kinase (p38 MAPK). It is hoped that this review will 
      provide a strong basis for further scientific exploration and development of 
      berberine's therapeutic potential against neurodegeneration.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Qin, Siru
AU  - Qin S
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
FAU - Tang, Huiling
AU  - Tang H
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
FAU - Li, Wei
AU  - Li W
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
FAU - Gong, Yinan
AU  - Gong Y
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
FAU - Li, Shanshan
AU  - Li S
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
FAU - Huang, Jin
AU  - Huang J
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
FAU - Fang, Yuxin
AU  - Fang Y
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
AD  - Acu-moxibustion and Tuina Department, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China
FAU - Yuan, Wenjuan
AU  - Yuan W
AD  - The First people's hospital of Lanzhou city, Gansu, China
FAU - Liu, Yangyang
AU  - Liu Y
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
AD  - Acu-moxibustion and Tuina Department, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China
FAU - Wang, Shenjun
AU  - Wang S
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
AD  - Acu-moxibustion and Tuina Department, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China
FAU - Guo, Yongming
AU  - Guo Y
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
AD  - Acu-moxibustion and Tuina Department, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China
FAU - Guo, Yi
AU  - Guo Y
AD  - College of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tianjin, China
FAU - Xu, Zhifang
AU  - Xu Z
AD  - Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China
AD  - Acu-moxibustion and Tuina Department, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China
LA  - eng
GR  - 2018015/Tianjin Municipal Bureau of Labor and Social Security/
GR  - 81704146, 81273868/National Natural Science Foundation of China (NSFC)/
GR  - 2018KJ024, 2017KJ150/Tianjin Education Commission/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0I8Y3P32UF (Berberine)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinases
MH  - Autophagy
MH  - *Berberine/pharmacology
MH  - Humans
MH  - *Neurodegenerative Diseases/drug therapy
MH  - Phosphatidylinositol 3-Kinases
OTO - NOTNLM
OT  - AMPK
OT  - Neurodegenerative diseases
OT  - apoptosis
OT  - berberine
OT  - glutamate excitotoxicity
OT  - mitochondrial disorder
OT  - neuroinflammation
OT  - oxidative stress
EDAT- 2020/05/24 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/05/24 06:00
PHST- 2019/12/16 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - CPD-EPUB-106864 [pii]
AID - 10.2174/1381612826666200523172334 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2020;26(39):5054-5066. doi: 10.2174/1381612826666200523172334.